6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of May 2005

FRESENIUS MEDICAL CARE CORPORATION

(Translation of registrant’s name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F þ          Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o          No þ

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82

TABLE OF CONTENTS

EXHIBIT 99.1

     On May 4, 2005 Fresenius Medical Care AG (the “Company”) issued a press release announcing its earnings results for the quarter ended March 31, 2005. A copy of the press release is furnished as Exhibit 99.1.

     The attached press release contains non-GAAP financial measures. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles. To supplement our first quarter 2005 consolidated financial results presented in accordance with generally Accepted Accounting Principles in the United States, or GAAP, we have used non-GAAP financial measure of (a) operating income excluding depreciation, amortization, and minority interests, and (b) free cash flow. These non-GAAP measures are provided to enhance the user’s overall understanding of our current financial performance and our prospects for the future. In addition, because we have historically reported certain non-GAAP financial measures in our financial results, we believe the inclusion of these non-GAAP financial measures provides consistency and comparability in our financial reporting to prior periods for which these non-GAAP financial measures were previously reported. These non-GAAP financial measures should not be used as a substitute for or be considered superior to GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures are included in the attached press release.

     The Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

     EXHIBITS

     Exhibit 99.1 Earning press release dated May 4, 2005

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: May 4, 2005

Fresenius Medical Care Aktiengesellschaft
By:	/s/ Dr. Ben Lipps
	Name:	Dr. Ben Lipps
	Title:	Chief Executive Officer and Chairman of the Management Board

By:	/s/ Lawrence A. Rosen
	Name:	Lawrence A. Rosen
	Title:	Chief Financial Officer

EX-99.1

Exhibit 99.1

Investor News	Fresenius Medical Care AG Investor Relations Else-Kröner-Str. 1 D-61352 Bad Homburg
	Contact:
	Oliver Maier
	Phone:	+ 49 6172 609 2601
	Fax:	+ 49 6172 609 2301
	E-mail: ir-fms@fmc-ag.com
	North America:
	Heinz Schmidt
	Phone:	+ 1 781 402 9000
		Ext.: 4518
	Fax:	+ 1 781 402 9741
	E-mail: ir-fmcna@fmc-ag.com
	Internet: http://www.fmc-ag.com
	May 04, 2005

Fresenius Medical Care Reports First Quarter 2005 Results;
Solid Start into the Year 2005

Summary First Quarter 2005:

Net Revenue	$1,609 million	+ 10	%
Operating income (EBIT)	$220 million	+ 11	%
Net income	$107 million	+ 18	%
Operating Cash Flow	$138 million	- 19	%
Free Cash Flow	$98 million	- 25	%

Fresenius Medical Care AG, May 04, 2005 1 of 13

Bad Homburg, Germany – Fresenius Medical Care AG (“the Company”) (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world’s largest provider of Dialysis Products and Services, today announced the results for the first quarter 2005.

Revenue

Total revenue for the first quarter 2005 increased by 10% (9% at constant currency) to $1,609 million. Total organic revenue growth worldwide was 7%. Consolidation resulting from FIN 46R interpretation added 2% to the revenue growth. Dialysis Care revenue grew by 10% to $1,162 million (9% at constant currency) in the first quarter of 2005. Dialysis Product revenue increased by 11% to $447 million (7% at constant currency) in the same period.

North America revenue increased by 9% to $1,088 million, compared to $1,003 million in the same period last year. Dialysis Care revenue increased by 8% to $968 million. The average revenue per treatment for the U.S. clinics increased by 2.5% to $293 in the first quarter 2005 (Q1 2004: $286). Same-store treatment growth was 3.8%. Dialysis Product revenue increased by 16% to $120 million.

International revenue was $521 million, up 14% from the first quarter of 2004 (8% at constant currency). Dialysis Care revenue reached $194 million, an increase of 22% (16% at constant currency). Dialysis Product revenue increased by 10% to $327 million (4% at constant currency).

Earnings

Operating income (EBIT) increased by 11% to $220 million resulting in an operating margin of 13.7% (Q1 2004: 13.6%).

Compared with the first quarter 2004, the operating margin in North America remained nearly unchanged at 13.4%. On a comparable basis (excluding FIN 46R consolidations) the operating margin in North America was at 13.7% compared to 13.5% in the first quarter 2004. In our International segment the margin increased by 20 basis points to 15.8% compared to the first quarter in the previous year.

Fresenius Medical Care AG, May 04, 2005 2 of 13

Group net interest expenses decreased by 9% to $42 million, compared to $47 million last year. This positive development was mainly attributable to a lower debt level in combination with lower interest rates.

Income tax expense was $70 million versus $60 million in the first quarter 2004, reflecting an effective tax rate of 39.2% compared to 39.4% in the first quarter of last year.

Net income in the first quarter 2005 was $ 107 million, an increase of 18%.

Earnings per share (EPS) in the first quarter 2005 rose by 18% to $1.11 per ordinary share ($0.37 per ADS), compared to $0.94 ($0.31 per ADS) in the first quarter of 2004. The weighted average number of shares outstanding was approximately 96.3 million.

Cash Flow

In the first quarter of 2005, the Company generated $138 million in net cash from operations compared to $171 million last year. The decrease was mainly due to higher income tax payments in North America.

A total of $40 million (net of disposals) was spent for capital expenditures. This resulted in a Free Cash Flow before acquisitions of $98 million compared to $130 million in the first quarter of 2004. The Free Cash Flow performance was driven by the increase in net income. The days sales outstanding (DSO) remained unchanged at 84 days in the first quarter 2005 compared to the fourth quarter 2004. Compared with the first quarter of the previous year DSO were reduced by 2 days.

A total of $22 million in cash was spent for acquisitions. The Free Cash Flow after acquisitions decreased by 13% to $76 million compared to $88 million last year.

For a complete overview of the first quarter 2005, please refer to the appendix.

Fresenius Medical Care AG, May 04, 2005 3 of 13

Patients — Clinics — Treatments

At the end of the first quarter 2005, Fresenius Medical Care served about 125,900 patients worldwide which represents an increase of 5%. North America provided dialysis treatments for ~87,000 patients (+4%) and the International segment for ~38,900 patients (+6%).

As of March 31, 2005, the Company operated a total of 1,630 clinics worldwide (1,140 clinics/+2% in North America and 490 clinics/+8% International).

Fresenius Medical Care AG performed approximately 4.72 million treatments, which represents an increase of 3% year over year. North America accounted for 3.25 million treatments (+3%) and the International segment for 1.47 million (+5%).

Outlook 2005

For the year 2005, the Company confirms its outlook before the impact of the Renal Care Group acquisition. The Company expects a revenue growth at constant currency between six and nine percent and net income growth in the low double-digit range.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: “Our results for the first quarter 2005 show a solid start for the year. We are pleased that all regions and business segments grew at or above market. Revenue growth in Europe and North America evidenced continued strong momentum. With this solid foundation we have initiated plans to increase our investments in the core dialysis business to assure strong financial growth.”

Fresenius Medical Care AG, May 04, 2005 4 of 13

Webcast of Analyst Meeting

Instead of a Conference Call only, Fresenius Medical Care will also host an Analyst Meeting on May 04, 2005 at 2.30 pm CET / 8.30 am EDT at its headquarters in Bad Homburg. The Company invites investors to listen to the live video webcast of the meeting at the Company’s website www.fmc-ag.com in the “Investor Relations” section. A replay will be available shortly after the meeting.

If you would like to participate via telephone, please call the following number on the day and at the time mentioned above:

+1 (706) 645 9185 (U.S./Canada and International Callers).

Fresenius Medical Care AG is the world’s largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,300,000 individuals worldwide. Through its network of approximately 1,630 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides Dialysis Treatment to approximately 125,900 patients around the globe. Fresenius Medical Care is also the world’s leading provider of Dialysis Products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care, visit the Company’s website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care AG, May 04, 2005 5 of 13

FRESENIUS MEDICAL CARE AG
 
STATEMENT OF EARNINGS
(in US-$ thousands, except share and
per share data)
(unaudited)

	Three months ended March 31,
	2005			2004			% Change
Net revenue
Dialysis Care		1,162,461			1,057,750			9.9	%
Dialysis Products		446,542			401,306			11.3	%
Total net revenue		1,609,003			1,459,056			10.3	%
Cost of revenue		1,070,034			977,098			9.5	%
Gross profit		538,969			481,958			11.8	%
Selling, general and administrative		305,738			271,469			12.6	%
Research and development		13,248			12,301			7.7	%
Operating income (EBIT)		219,983			198,188			11.0	%
Interest income		(2,245	)		(2,874	)		(21.9	%)
Interest expense		44,532			49,577			(10.2	%)
Interest expense, net		42,287			46,703			(9.5	%)
Earnings before income taxes and minority interest		177,696			151,485			17.3	%
Income tax expense		69,643			59,697			16.7	%
Minority interest		582			679			(14.3	%)
Net income		107,471			91,109			18.0	%
Operating income (EBIT)		219,983			198,188			11.0	%
Depreciation and amortization		59,711			56,842			5.0	%
EBITDA		279,694			255,030			9.7	%
Total bad debt expenses		29,983			30,204
Earnings per Ordinary share		$1.11			$0.94			17.9	%
Earnings per Ordinary ADS		$0.37			$0.31			17.9	%
Earnings per Preference share		$1.13			$0.96			17.6	%
Earnings per Preference ADS		$0.38			$0.32			17.6	%
Weighted average number of shares
Ordinary shares		70,000,000			70,000,000
Preference shares		26,330,125			26,215,699
Percentages of revenue
Cost of revenue		66.5%			67.0%
Gross profit		33.5%			33.0%
Selling, general and administrative		19.0%			18.6%
Research and development		0.8%			0.8%
Operating income (EBIT)		13.7%			13.6%
Interest expense, net		2.6%			3.2%
Earnings before income taxes and minority interest		11.0%			10.4%
Income tax expense		4.3%			4.1%
Minority interest		0.0%			0.0%
Net income		6.7%			6.2%
EBITDA		17.4%			17.5%

Fresenius Medical Care AG, May 04, 2005 6 of 13

FRESENIUS MEDICAL CARE AG

SEGMENT AND OTHER INFORMATION
(in US-$ million)
(unaudited)

	Three months ended March 31,
	2005			2004*			% Change
Net revenue
North America		1,088			1,003			8.5	%
International		521			456			14.0	%
Total net revenue		1,609			1,459			10.3	%
Operating income (EBIT)
North America		146			136			7.8	%
International		82			71			15.6	%
Corporate		(8	)		(9	)		(2.2	%)
Total operating income (EBIT)		220			198			11.0	%
Operating income in percentage of revenue
North America		13.4	%		13.5	%
International		15.8	%		15.6	%
Total		13.7	%		13.6	%
Employees
Full-time equivalents (March 31 compared to Dec.31)		44,957			44,526

RECONCILIATION OF NON US-GAAP

FINANCIAL MEASURES TO THE MOST DIRECTLY

COMPARABLE US-GAAP FINANCIAL MEASURES
(in US-$ million)
(unaudited)

	Three months ended March 31,
	2005		2004*		% Change
Segment information North America
Net revenue		1,088		1,003
Costs of revenue and research and development		785		729
Selling, general and administrative		157		138
Costs of revenue and operating expenses		942		867
Operating income (EBIT)		146		136
Annualized EBITDA
Operating income (EBIT) last twelve months		874		690
Depreciation and amortization last twelve months		236		212
Non cash charges		11		10
Annualized EBITDA		1,121		912

*  The management responsibility for the Mexican business has been transferred from the segment International to the segment North America starting January 1, 2005. 2004 segment information has been restated accordingly.

Fresenius Medical Care AG, May 04, 2005 7 of 13

FRESENIUS MEDICAL CARE AG

BALANCE SHEET
(in US-$ million)

	March 31,			December 31,
	2005			2004
	(unaudited)
Assets
Current assets		2,468			2,446
Intangible assets		4,039			4,047
Other non-current assets		1,387			1,469
Total assets		7,894			7,962
Shareholders’ equity and liabilities
Current liabilities		1,867			1,938
Long-term liabilities		2,312			2,389
Shareholders’ equity		3,715			3,635
Total shareholders’ equity and liabilities		7,894			7,962
Equity/assets ratio:		47	%		46	%
Debt
Short-term borrowings		326			419
Short-term borrowings from related parties		6			6
Current portion of long-term debt and capital lease obligations		241			230
Long-term debt and capital lease obligations, less current portion		526			545
Trust Preferred Securities		1,244			1,279
Total debt		2,343			2,479

Fresenius Medical Care AG, May 04, 2005 8 of 13

FRESENIUS MEDICAL CARE AG

CASH FLOW STATEMENT
(in US-$ million)
(unaudited)

	Three months ended March 31,
	2005			2004
Operating activities
Net income		107			91
Depreciation/amortization		60			57
Change in working capital and other non cash items		(29	)		23
Cash Flow from operating activities		138			171
Investing activities
Purchases of property, plant and equipment		(44	)		(43	)
Proceeds from sale of property, plant and equipment		4			2
Capital expenditures, net		(40	)		(41	)
Free Cash Flow		98			130
Acquisitions, net of cash acquired		(22	)		(42	)
Free Cash Flow after investing activities		76			88
Financing activities
Change in accounts receivable securitization program		(71	)		(113	)
Change in intercompany debt		—			50
Change in other debt		(16	)		(14	)
Proceeds from exercise of stock options		4			—
Cash Flow from financing activities		(83	)		(77	)
Effects of exchange rates on cash		(1	)		(2	)
Net increase (decrease) in cash		(8	)		9
Cash at beginning of period		59			48
Cash at end of period		51			57

Fresenius Medical Care AG, May 04, 2005 9 of 13

FRESENIUS MEDICAL CARE AG

QUARTERLY PERFORMANCE SCORECARD – REVENUE
(in US-$ thousands, except per-treatment revenue)

	Three months ended March 31,
	2005			cc			2004*			cc
North America
Net revenue		1,088,184						1,002,601
Growth year-over-year		8.5	%					7.2	%
Dialysis Care		968,561						899,351
Growth year-over-year		7.7	%					9.0	%
U.S. per treatment		293						286
Per treatment		291						284
Sequential growth		1.0	%					2.2	%
Growth year-over-year		2.4	%					2.8	%
Dialysis Products
incl. internal sales		207,678						195,918
less internal sales		(88,055	)					(92,668	)
External sales		119,623						103,250
Dialysis Products
incl. internal sales		207,678						195,918
Growth year-over-year		6.0	%					0.6	%
External sales		119,623						103,250
Growth year-over-year		15.9	%					(6.1	)%
International
Net revenue		520,818						456,455
Growth year-over-year		14.1	%		8.4	%		25.2	%		9.9	%
Dialysis Care		193,900						158,398
Growth year-over-year		22.4	%		16.0	%		32.9	%		17.0	%
Per treatment		132			125			113			100
Sequential growth		2.2	%					7.7	%
Growth year-over-year		16.8	%		10.7	%		19.2	%		5.0	%
Dialysis Products
incl. internal sales		367,322						331,090
less internal sales		(40,404	)					(33,033	)
External sales		326,918						298,057
Dialysis Products
incl. internal sales		367,322						331,090
Growth year-over-year		10.9	%		5.4	%		22.1	%		7.0	%
External sales		326,918						298,057
Growth year-over-year		9.7	%		4.4	%		21.5	%		6.4	%

cc = at constant exchange rates
*	The management responsibility of the Mexican business has been transferred from the segment International to the segment North America starting January 1, 2005. 2004 segment information has been restated accordingly.

Fresenius Medical Care AG, May 04, 2005 10 of 13

FRESENIUS MEDICAL CARE AG

QUARTERLY PERFORMANCE SCORECARD — DIALYSIS CARE VOLUME

	Three months ended March 31,
	2005			2004*
North America
Number of treatments		3,250,110			3,170,088
Treatments per day		42,205			40,642
Per day sequential growth		0.4	%		0.3	%
Per day year-over-year growth		3.8	%		3.3	%
of which:
- Acquisitions		1.0	%		1.2	%
- Same store growth year-over-year		3.8	%		2.9	%
- Adjustment for closed/sold facilities, yield and other		(1.0	)%		(0.8	)%
International
Number of treatments		1,466,672			1,399,400
Same store growth year-over-year		5.6	%		5.6	%

FRESENIUS MEDICAL CARE AG

QUARTERLY PERFORMANCE SCORECARD – EXPENSES

	Three months ended March 31,
	2005			2004*
North America
Costs of revenue and operating expenses
Percent of revenue		86.6	%		86.5	%
Selling, general and administrative
Percent of revenue		14.4	%		13.7	%
Bad debt expenses
Percent of revenue		2.7	%		2.7	%
Dialysis Care operating expenses/Treatment (in US-$)		253			248
Sequential growth		1.5	%		3.7	%
Growth year-over-year		1.9	%		2.2	%
Total Group
Costs of revenue and operating expenses
Percent of revenue		86.3	%		86.4	%
Selling, general and administrative
Percent of revenue		19.0	%		18.6	%
Effective tax rate		39.2	%		39.4	%

* The management responsibility for the Mexican business has been transferred from the segment International to the segment North America starting January 1, 2005. 2004 segment information has been restated accordingly.

Fresenius Medical Care AG, May 04, 2005 11 of 13

FRESENIUS MEDICAL CARE AG

QUARTERLY PERFORMANCE SCORECARD — CASH FLOW/INVESTING ACTIVITIES
(in US-$ thousands,
except number of de novos)

	Three months ended March 31,
	2005			2004*
Total Group
Operating Cash Flow		138,475			171,322
Percent of revenue		8.6	%		11.7	%
Free Cash Flow, before acquisitions		98,430			130,408
Percent of revenue		6.1	%		8.9	%
Acquisitions, net		21,988			42,401
Capital expenditures, net		40,045			40,914
Percent of revenue		2.5	%		2.8	%
Maintenance		20,537			18,757
Percent of revenue		1.3	%		1.3	%
Growth		19,508			22,157
Percent of revenue		1.2	%		1.5	%
Number of de novos		23			14
North America		13			7
International		10			7

FRESENIUS MEDICAL CARE AG

QUARTERLY PERFORMANCE SCORECARD — BALANCE SHEET

	Three months ended March 31,
	2005			2004*
Total Group
Debt (in US-$ million)		2,343			2,651
Debt/EBITDA		2.1			2.6
North America
Days sales outstanding		66			71
Sequential development		(1.5	)%		(1.4	)%
Year-over-year development		(7.0	)%		(10.1	)%
International
Days sales outstanding		123			121
Sequential development		3.4	%		(4.7	)%
Year-over-year development		1.7	%		(11.0	)%

* The management responsibility for the Mexican business has been transferred from the segment International to the segment North America starting January 1, 2005. 2004 segment information has been restated accordingly.

Fresenius Medical Care AG, May 04, 2005 12 of 13

FRESENIUS MEDICAL CARE AG

QUARTERLY PERFORMANCE SCORECARD

	Three months
	ended
	March 31,
	2005			2004
Clinical Performance
North America
Urea reduction > = 65%		91	%		90	%
Single Pool Kt/v > 1.2		94	%		94	%
Hemoglobin > = 11g/dl		81	%		77	%
Albumin > = 3.5 g/dl*		78	%		78	%
Hospitalization Days per Patient (FY 2004 vs. FY 2003)		13.1			13.4
Demographics
North America
Average age (yr)		61			61
Average time on dialysis (yr)		3.4			3.3
Average body weight (kg)		77			76
Prevalence of diabetes		52	%		52	%

*  International standard BCR CRM470

Fresenius Medical Care AG, May 04, 2005 13 of 13

  GRAPHIC 3 f00969f0096901.gif GRAPHIC begin 644 f00969f0096901.gif M1TE&.#EA'P%*`,0``).2DEU<7,K)R.9&F> M:*JN;.N.@C=U0VW?>*[O_%XAA<-K2"P:C\BD`W,5 MC`J)DY25A0F,&'(0$78%!):AHJ-4`(P5<:9V"Z2MKJ\L!`AV"&=H%)UK#["\ MO;P,C%IN@FL)OL?(H8MK$;9?%(P-R=/4A@=D:Q=H$YZ@U=_@8:IK%&`#C`SA MZNM;LVL68-QK`>SU]D7# M'D9!!$0E5&-9V[V\$DQ%37#"0M>\>R3C&HL8M_2]?2*!H=C"A>7J_?\O;)7% M",1`!N"!+"S3S/\'&JPA#8(0JL!90A_(TUZ$&)H0WQJP9>@A">[(<]B')'Z0 MCSS"E?CA$]S@IF*&8TQ`VHLE+C!!6#22V&&.//;HXX]`!BGDD$06:>212":I M)!$&3)5'BM7DT5<<"01@)8XD'&"EE08N(>4(34[I19,NFD"``0[,%<`"(:L,`:B,*` M3:M@Q(H"`:*"PD`>)22PAP%MCG#F'CN6\*L>R7Z0@*@?$+``LR:(:N#_`;V6 MP*L`Q0HP;+$GY$.9!W3FHX`J6"Z;1[,CJ+N`$*\^VZ4(!TR;Q[OA\C'O![H: MBTVM)&#G0`GU(@NNJ$)X"T"*"=@+`+%^8L%"/@R4-4("^ZQ1@)CS]8/`O`L4 MNL;')"QC@,AL=/DJNI/J>7'&M*Z0CP#+U.?.`2R+P`#,'A20+,:,;/SJGR00 M\.8:F`'-SP-=]BL"=G>>\*5%XP;-\0=8`)!G2U7V(XS3+;,QYV$".I"'`MAT MB-V:`AB`T(5$]7PN`.,")4)9!5!_P.CCDO=W1*?,"[`!\UI@*B? M5SH">V,;DP`V`7B.C1;+;.F[HR(LID!(3Q6`XP&SM+?(Z2+,Z@%L^3R0HL`1 MLY'B,F'U+7OBLF.WXU.`ADV(\PX$1AK+BW=Y.QO5<[P^N1&/B!!YS@K^-.AX MIHZZ!RA@3\2K.LL:W_J3H@=@@6,$,*!`CL:/P^2#>1_`CHNP,Z5%&*]H"!,! M0O:%$&^8K`3.RQ[\.K:]X/G->0UHD[Q4`#A^S0D+#V*9\Z[V`548XRT>B-H' MG*>Y$>(0@CNT4L*`E3_^5:]_?G,,`-(EP-GU3(7CJ1;HL">J*E81,OG`S?SZ M@!!AC*,`N6,`E-SA!___N="(?TNB]K#4P@GE4`$+V%>X_.9&\K!,45S$7Q9- M@,,>D@V&+>`5F0*@0#2>$8DE?$$"EN6``.QN@(!2Q=SX@(5&ZB\%>RR91D8$ M`)XA0$P;64J_6HBU$=8PB2;<7@*JIK'AL3")SC/D'36BA4R68&@C5$69BA8W M1KA#DX8D`4)81P)[M8MGCW1B)#<)MC1*JGJ3[,/5#O`K1R)-!$@#1$M&J493 MY@Q,J(R6`!:@@'W,:(XE7`2B9ID%;9JHB;9TN0+3->!UQE`%,%$`-0FE MYP,"@B.T;%G*948.$`9H)O=P$[=F;4L(.%L8'?HC`@6""UO2EBV;CVM2U0$`"`(D"/'U,Y,!`*L8\FB-L^3R`Z&HY@ M7,)8:=@P`U/GL0YA"DTE;J)7+(2D(Q^;$L$LKD+/HAE0>9=,I0@YB84=O6^; M3_1H.)V)*Q(2@GHE$.H'QH6EWL5O!-CHTE/:8*Y@86.G)W#>QIQ0%`]BH5A` MA23!^@K"*685G2Y"R`/$2("*O0L]XQ@`"-7<:CUE>`A<5V'F\-8,\,<(`SN6-*V)B2 ML$;KUV`6,8>A$E4GV6.@^4$TLPX*"4Q/R0;>FDBQNH>4&3R%Z8_R4#(LAK>AH18XPF!8*Q`7+4\98DNLH`U+2&/S[!`5I\8C&%```[ ` end -----END PRIVACY-ENHANCED MESSAGE-----